Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits colitis disease progression and colon inflammation, lowers inflammatory mucosal cytokines, and reduces expression of IBD-associated genes in a colitis model

Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with Phase 1 clinical data expected in Q1 2025

Poster presentation today at 12:30 pm ET 

BOSTON, May 21, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data at Digestive Disease Week (DDW) 2024, being held May 18-21 in Washington, D.C. The data showed that MRT-6160-mediated degradation of VAV1 inhibited disease progression in a T-cell transfer murine model of colitis. VAV1 is a key signaling protein downstream of both the T-and B-cell receptors and its degradation has potential to treat multiple T-cell and/or Th17 mediated autoimmune and inflammatory diseases, including ulcerative colitis (UC).

“VAV1 is a well-validated target with significant therapeutic potential in autoimmune and inflammatory diseases but is generally considered undruggable via conventional modalities. These promising preclinical data support our hypothesis that VAV1 is an important target in inflammatory bowel disease (IBD) and also demonstrate MRT-6160's ability to potentially address the underlying disease biology and provide therapeutic benefit,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. “We’re particularly encouraged to see significant reductions in colitis disease activity and progression as well as corroborating data demonstrating the reduction of pro-inflammatory cytokines and decreased expression of multiple IBD-associated genes. MRT-6160 is on track for an IND submission this quarter with initiation of a Phase 1 single ascending dose/multiple ascending dose (SAD/MAD) study mid-year. We look forward to sharing clinical data from this program in Q1 2025.”

The poster, entitled “MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a T-cell Transfer Mediated Murine Colitis Model Concomitant with Reduced Calprotectin Expression” (Poster Number Tu1727), will be presented today by Marisa Peluso, Director, Target and Discovery Biology for Monte Rosa Therapeutics, during the Session, “Animal Models of IBD: Pre-Clinical Treatment of Intestinal Inflammation,” at 12:30 pm ET.